BRAIN Biotech Stock

BRAIN Biotech FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of BRAIN Biotech (BNN.DE) as of Aug 23, 2026 is 91.67 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 47.74 % — a change of 92.02% (higher).

FCF Conversion

91.67 %

YoY

92.02%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of BRAIN Biotech is 2026 91.67 % . FCF Conversion Rate (FCF/EBITDA) of BRAIN Biotech was 2025 47.74 % . It decreases by 92.02% higher compared to the previous year.

The BRAIN Biotech FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
83.75 EUR
Jan 1, 2019
95.45 EUR
Jan 1, 2020
78.75 EUR
Jan 1, 2021
103.94 EUR
Jan 1, 2022
114.83 EUR
Jan 1, 2023
82.81 EUR
Jan 1, 2024
47.74 EUR
Jan 1, 2025
91.67 EUR
The BRAIN Biotech FCF Conversion history
YEARFCF ConversionYoY
91.67 %+92.02%
47.74 %-42.35%
82.81 %-27.88%
114.83 %+10.47%
103.94 %+31.99%
78.75 %-17.49%
95.45 %+13.97%
83.75 %+17.71%
71.15 %+5.42%
67.49 %-18.03%
82.34 %-5.56%
87.19 %
Access this data via the Eulerpool API

BRAIN Biotech Stock analysis

What does BRAIN Biotech do? The company BRAIN Biotechnology Research and Information Network AG is a German company specializing in biotechnology. The company was founded in 1993 and is headquartered in Zwingenberg, Germany. BRAIN has been listed on the Frankfurt Stock Exchange since 2006 and has over 500 employees worldwide. The history of BRAIN dates back to the 1980s when the Senckenberg Institute for Biodiversity and Climate Research in Frankfurt developed a new method for isolating microorganisms. These are called extremophilic bacteria and fungi, which live in extreme environments such as hot springs or salty soils and produce special enzymes. These enzymes can be used in various applications, such as the food industry or the development of new drugs. BRAIN has further developed this method and built an extensive portfolio of enzymes, microorganisms, and natural substances. The company is divided into three areas: 1. BioIndustrial: Enzymes and microorganisms for industrial applications are developed here, such as for the production of detergents, paper, or bioethanol. 2. BioScience: This area focuses on the research of natural substances and active ingredients from microorganisms for the pharmaceutical and cosmetics industries. 3. Consumer Products: BRAIN develops products for end consumers here, such as probiotics or enzyme preparations for digestion promotion. BRAIN works closely with leading companies to develop innovative solutions for their needs. The company is not only focused on the development of new products but also on the optimization of existing processes. BRAIN relies on sustainable and environmentally friendly production. An example of a product developed by BRAIN is an enzyme used in the production of fruit juice. This enzyme breaks down pectin, which is found in many types of fruit and causes the juice to become cloudy. By using this enzyme, the juice can be made clearer and more durable without the need for artificial additives. BRAIN also uses a special enzyme in the production of soy milk to improve taste and consistency. Overall, BRAIN has filed over 600 patents and works with more than 170 customers in various industries. The company is committed to preserving biodiversity and promoting sustainability in production. In summary, BRAIN Biotechnology Research and Information Network AG is a company specializing in the research and development of enzymes, microorganisms, and natural substances. The company has a long history and can look back on successful collaborations with leading companies in various industries. BRAIN focuses on sustainability and environmental compatibility in production and has a broad portfolio of products that can be used in various applications. BRAIN Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BRAIN Biotech stock

FCF Conversion Rate (FCF/EBITDA) of BRAIN Biotech is 91.67 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of BRAIN Biotech changed from 47.74 % to 91.67 %, representing a 92.02% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) BRAIN Biotech since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s BRAIN Biotech with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — BRAIN Biotech

All Key Metrics — BRAIN Biotech